Antidiabetic activity of zinc oxide and silver nanoparticles on streptozotocin-induced diabetic rats.
The use of nanoparticles in medicine is an attractive proposition. In the present study, zinc oxide and silver nanoparticles were evaluated for their antidiabetic activity. Fifty male albino rats with weight 120 ± 20 and age 6 months were used. Animals were grouped as follows: control; did not receive any type of treatment, diabetic; received a single intraperitoneal dose of streptozotocin (100 mg/kg), diabetic + zinc oxide nanoparticles (ZnONPs), received single daily oral dose of 10 mg/kg ZnONPs in suspension, diabetic + silver nanoparticles (SNPs); received a single daily oral dose of SNP of 10 mg/kg in suspension and diabetic + insulin; received a single subcutaneous dose of 0.6 units/50 g body weight. Zinc oxide and silver nanoparticles induce a significant reduced blood glucose, higher serum insulin, higher glucokinase activity higher expression level of insulin, insulin receptor, GLUT-2 and glucokinase genes in diabetic rats treated with zinc oxide, silver nanoparticles and insulin. In conclusion, zinc oxide and sliver nanoparticles act as potent antidiabetic agents.
Department of Biological Sciences, Faculty of Science, King Abdulaziz University, North Campus, P.O. Box 11508, Jeddah 21463, Saudi Arabia. alkaladi@kau.edu.sa.
Ali
A
Alkaladi
Department of Biochemistry, Faculty of Veterinary Medicine, Zagazig University, Zagazig 44511, Egypt. drasr_bio@yahoo.com.
Aaser Mohamed
AM
Abdelazim
Department of Biological Sciences, Faculty of Science, King Abdulaziz University, North Campus, P.O. Box 11508, Jeddah 21463, Saudi Arabia. mafifi@kau.edu.sa.
Mohamed
M
Afifi
D000818:Animals; D001786:Blood Glucose; D003921:Diabetes Mellitus, Experimental / Q000188:drug therapy / Q000235:genetics / Q000378:metabolism*; D015870:Gene Expression; D005941:Glucokinase / Q000235:genetics / Q000378:metabolism; D007004:Hypoglycemic Agents / Q000494:pharmacology*; D007328:Insulin / Q000008:administration & dosage / Q000097:blood; D007515:Islets of Langerhans / Q000378:metabolism / Q000473:pathology; D008297:Male; D053768:Metal Nanoparticles / Q000737:chemistry*; D051381:Rats; D012834:Silver / Q000008:administration & dosage*; D015034:Zinc Oxide / Q000008:administration & dosage*
D001786:Blood Glucose; D007004:Hypoglycemic Agents; D007328:Insulin; D012834:Silver; D005941:Glucokinase; D015034:Zinc Oxide